Therapeutic Response

Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Carboplatin in combination with Cemiplimab and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Libtayo (cemiplimab) [product monograph]. HC. Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.
Libtayo (cemiplimab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.